Cargando…

Description of the consumption of toxics in patients with assertive community treatment and prolonged release treatment

INTRODUCTION: The Assertive Community Treatment (ACT) was developed by Leonard Stein and Mary Ann. The objective is the treatment of serious Mental Disorders in an integral way and in the community. OBJECTIVES: The Assertive Community Treatment (ACT) was developed by Leonard Stein and Mary Ann. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Garcia, L., Rodriguez, C., Willems, A.I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9480347/
http://dx.doi.org/10.1192/j.eurpsy.2021.2182
_version_ 1784791033762021376
author Garcia, L.
Rodriguez, C.
Willems, A.I.
author_facet Garcia, L.
Rodriguez, C.
Willems, A.I.
author_sort Garcia, L.
collection PubMed
description INTRODUCTION: The Assertive Community Treatment (ACT) was developed by Leonard Stein and Mary Ann. The objective is the treatment of serious Mental Disorders in an integral way and in the community. OBJECTIVES: The Assertive Community Treatment (ACT) was developed by Leonard Stein and Mary Ann. The objective is the treatment of serious Mental Disorders in an integral way and in the community. METHODS: This is a retrospective study with a total of 69 patients whose main diagnosis is Schizophrenia undergoing CT follow-up in 2018-2019. The data obtained have been analyzed by the SPSS statistical program. RESULTS: Our sample is mainly composed of men (60.9%) with an average age of 48 years (+ - 11.56). The main diagnosis is schizophrenia (62.3%) and the most commonly used long-term injectable treatment is paliperidone palmitate with a dose range of 150mg. Of the total number of patients, 29% of the cases did not maintain active use of any toxic, and the most commonly used toxic is tobacco (49.3% of cases). CONCLUSIONS: The inclusion of patients in a ACT program requires a diagnosis of severe Mental Disorder and poor therapeutic adherence. After analyzing our data, we observed that most of them also have active toxic consumption and high doses of psychotropic drugs. DISCLOSURE: No significant relationships.
format Online
Article
Text
id pubmed-9480347
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-94803472022-09-29 Description of the consumption of toxics in patients with assertive community treatment and prolonged release treatment Garcia, L. Rodriguez, C. Willems, A.I. Eur Psychiatry Abstract INTRODUCTION: The Assertive Community Treatment (ACT) was developed by Leonard Stein and Mary Ann. The objective is the treatment of serious Mental Disorders in an integral way and in the community. OBJECTIVES: The Assertive Community Treatment (ACT) was developed by Leonard Stein and Mary Ann. The objective is the treatment of serious Mental Disorders in an integral way and in the community. METHODS: This is a retrospective study with a total of 69 patients whose main diagnosis is Schizophrenia undergoing CT follow-up in 2018-2019. The data obtained have been analyzed by the SPSS statistical program. RESULTS: Our sample is mainly composed of men (60.9%) with an average age of 48 years (+ - 11.56). The main diagnosis is schizophrenia (62.3%) and the most commonly used long-term injectable treatment is paliperidone palmitate with a dose range of 150mg. Of the total number of patients, 29% of the cases did not maintain active use of any toxic, and the most commonly used toxic is tobacco (49.3% of cases). CONCLUSIONS: The inclusion of patients in a ACT program requires a diagnosis of severe Mental Disorder and poor therapeutic adherence. After analyzing our data, we observed that most of them also have active toxic consumption and high doses of psychotropic drugs. DISCLOSURE: No significant relationships. Cambridge University Press 2021-08-13 /pmc/articles/PMC9480347/ http://dx.doi.org/10.1192/j.eurpsy.2021.2182 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Garcia, L.
Rodriguez, C.
Willems, A.I.
Description of the consumption of toxics in patients with assertive community treatment and prolonged release treatment
title Description of the consumption of toxics in patients with assertive community treatment and prolonged release treatment
title_full Description of the consumption of toxics in patients with assertive community treatment and prolonged release treatment
title_fullStr Description of the consumption of toxics in patients with assertive community treatment and prolonged release treatment
title_full_unstemmed Description of the consumption of toxics in patients with assertive community treatment and prolonged release treatment
title_short Description of the consumption of toxics in patients with assertive community treatment and prolonged release treatment
title_sort description of the consumption of toxics in patients with assertive community treatment and prolonged release treatment
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9480347/
http://dx.doi.org/10.1192/j.eurpsy.2021.2182
work_keys_str_mv AT garcial descriptionoftheconsumptionoftoxicsinpatientswithassertivecommunitytreatmentandprolongedreleasetreatment
AT rodriguezc descriptionoftheconsumptionoftoxicsinpatientswithassertivecommunitytreatmentandprolongedreleasetreatment
AT willemsai descriptionoftheconsumptionoftoxicsinpatientswithassertivecommunitytreatmentandprolongedreleasetreatment